Clinical Trial: New Antibiotic to Treat Patients With Community-acquired Pneumonia Due to a Specific Bacteria (S. Pneumoniae Pneumonia)
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: Linezolid in the Treatment of Penicillin-Resistant Streptococcus Pneumoniae Pneumonia: An Open-Label, Non-Comparator Study
Brief Summary: This study will treat patients who have a community-acquired pneumonia that is due to a specific bacteria (S. pneumoniae)
Detailed Summary:
Sponsor: Pfizer
Current Primary Outcome:
- To assess the microbiologic efficacy of linezolid in the treatment of patients with pneumonia caused by penicillin-resistant Streptococcus pneumoniae (PRSP).
- Additionally, microbiologic efficacy will be assessed in all pneumonia patients infected with S pneumoniae SP) and in those infected with penicillin-sensitive (PSSP) and penicillin-intermediate (PISP) S pneumoniae.
Original Primary Outcome:
Current Secondary Outcome: To assess clinical efficacy and safety in pneumonia patients infected with S pneumoniae.
Original Secondary Outcome:
Information By: Pfizer
Dates:
Date Received: May 2, 2002
Date Started: December 2001
Date Completion:
Last Updated: April 25, 2011
Last Verified: April 2011
